NeuroSense Secures South Korean Patent for ALS Drug PrimeC
Event summary
- NeuroSense received Korean Patent Number 10-2969898 for PrimeC's composition, covering formulation, manufacturing, and ALS treatment use.
- The patent provides protection in South Korea through 2042, expanding NeuroSense's global IP portfolio.
- PrimeC is advancing toward Phase 3 development after receiving FDA clearance for its pivotal PARAGON study in ALS.
- Phase 2b PARADIGM study showed PrimeC slowed disease progression and demonstrated biological activity across ALS biomarkers.
The big picture
NeuroSense's South Korean patent strengthens its global IP position as it prepares for Phase 3 trials of PrimeC, a drug targeting multiple ALS progression mechanisms. The patent follows similar grants in Japan, Brazil, Australia, and the U.S., underscoring the company's strategic focus on securing broad market protection. The ALS treatment market remains underserved, with significant unmet needs and a growing patient population, making PrimeC's development a critical watchpoint for investors and operators in neurodegenerative disease therapeutics.
What we're watching
- Global IP Strategy
- How NeuroSense will leverage this patent in South Korea's pharmaceutical market and whether it can secure similar protections in other key regions.
- Clinical Trial Execution
- The pace at which NeuroSense can enroll participants and generate data from the Phase 3 PARAGON study in ALS.
- Commercialization Pathway
- Whether PrimeC's multi-target mechanism of action will translate into long-term commercial success in the competitive ALS treatment landscape.
Related topics